

"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA. Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250 e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

SAFETY DATA SHEET

Section 1: Identification					
Section 1, Identification					
GHS Product identifier	Lansoprazole Delayed-Release Capsules USP, 15 mg and 30 mg				
Trade Name	Not Applicable				
Chemical name	2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2 pyridyl]methyl] sulfinyl] benzimidazole $\underbrace{\bigvee_{N}}_{N} \underbrace{\bigvee_{N}}_{H_{3}C} \underbrace{\bigvee_{N}}_{OCH_{2}CF_{3}}$ Lansoprazole				
Recommended use/Therapeutic Category	Antacid				
Restriction on Use/Contraindications	Lansoprazole is contraindicated in patients with known severe hypersensitivity to any component of the formulation of lansoprazole delayed- release capsules.				
Manufacturer	Hetero Labs Limited, Unit-III Plot No. 22-110, Part-II, IDA, Jeedimetla, Hyderabad 500055, Telangana, India (IND).				
Distributor	Camber Pharmaceuticals, Inc., Piscataway, NJ, 08854.				
Section 2: Hazard	(s) Information				
Dose and Administration	Lansoprazole is available as a capsule in 15 mg and 30 mg strengths. Lansoprazole should be taken before eating. You should swallow lansoprazole delayed-release capsules whole. Do not crush or chew lansoprazole delayed-release capsules. If you have trouble swallowing a whole capsule, you can open the capsule and take the contents with certain foods or juices. See the "Instructions for Use" at the end of this Medication Guide for instructions on how to take lansoprazole delayed-release capsules with certain foods and juices.				
Adverse Effects	Most commonly reported adverse reactions (≥ 1%): diarrhea, abdominal pain, nausea and constipation.				
Over Dose Effect	Lansoprazole is not removed from the circulation by hemodialysis. In one reported overdose, a patient consumed 600 mg of lansoprazole with no adverse reaction.				
Medical Conditions	Tell your doctor if you: have been told that you have low magnesium levels in your blood, have liver problems, have any other medical conditions,				



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA. Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250 e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

			known if will harm plan to br passes int should d delayed-re should no best way lansopraze	lansoprazole delay your unborn baby, eastfeed. It is not k to your breast milk. ecide if you will elease capsules o t do both. Talk to y to feed your ole delayed-release	me pregnant. It is not red-release capsules are breastfeeding or nown if lansoprazole You and your doctor take lansoprazole or breastfeed. You rour doctor about the baby if you take capsules.
			Lansopraz affect ho medicines	, vitamins, and l zole delayed rele w other medicine	nd nonprescription nerbal supplements. ase capsules may s work, and other insoprazole delayed-
			(Reyataz [®] contains (Coumadi theophyllin Theochron	^{\$\$}), digoxin (Lanoxi iron, ketoconazole n ^{®\$} ,Jantoven ^{®\$}), ta n ^{®\$} , Theolair ^{®\$}),	
			medicines that you t doctor ar medicine.	if you are not sure. take. Keep a list of nd pharmacist whe	ist for a list of these Know the medicines f them to show your en you get a new
Contraindications			known se of the form capsules.	vere hypersensitivit nulation of lansopra	ated in patients with by to any component zole delayed-release
Pregnancy Comments			in pregna		ell-controlled studies rug should be used ly needed.
Pregnancy Category			В		
Sect	ion 3: Comp	osition/Inf	ormation	n on Ingredien	ts
Principle Component	Lansoprazole			CA	S No.: 103577-45-3
Ingredient	CAS Number	EU EINECS List		GHS Classification	%
Hard gelatin capsules	Mixture	Not Listed		Not Listed	*
Additional Information	al Information * Proprietary Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety				

workplace safety.



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA. Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250 e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.					
Section 4: First-Aid Measures					
	Inhalation				
	Remove to fresh air. If not breathing give artificial respiration. If breathing is difficult, give oxygen. Seek medical attention.				
General	Contact with skin.				
	Immediately wash skin with soap and copious amounts of water for at least 15 minutes. If irritation persists, seek medical attention.				
	Contact with eyes Immediately flush eyes with copious amounts of water for at least 15 minutes. Seek medical advice.				
	Ingestion If swallowed, wash out mouth with water, provided person is conscious. Seek medical advice.				
	Remove and wash/dispose of contaminated clothing promptly.				
Overdose Treatment	Lansoprazole is not removed from the circulation by hemodialysis. In one reported overdose, a patient consumed 600 mg of lansoprazole with no adverse reaction.				
Section 5: Fire-Fig	hting Measures				
Flash point : Not Found	Upper Flammable Limit: Not Found				
Auto-Ignition Temperature: Not Found	Lower Flammable Limit: Not Found				
Extinguishing Media: Water Spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and material.	Fire and Explosion Hazard: This material is assumed to be combustible at high temperature.				
Fire Fighting Procedure	As with all fires, evacuate personnel to a safe area. Fire fighter should use self-contained breathing equipment and protective clothing.				
Section 6: Accidental					
Section 6, Accidental release measures					
Spill Response	Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site.				
Section 7: Handli	ng and Storage				



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA. Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250 e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

Section 7 Handling and starses		
Section 7, Handling and storage	Store at 20° to 25°C (68° to 77°F). Protect from	
Storage	moisture.	
Incompatibilities	Reacting with oxidizing substance.	
Section 8: Expo	sure Controls/Personal Protection	
Section 8, Exposure controls/personal	protection	
Respiratory Protection	Protection from inhalation is not normally necessary. If ventilation is inadequate or dust is likely to generate, use of suitable dust mask would be appropriate.	
Skin Protection	Skin protection is not normally necessary, however it is good practice to avoid contact with chemical to use suitable gloves when handling.	
Eye protection	Eye protection is not normally necessary. If concerned wear protective goggles or glasses. Wash hands prior to touching eye and in particular handling contact lenses.	
Protective Clothing	Protective clothing is not normally necessary, however it is good practice to use apron.	
Engineering Control	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.	
Section 9: Ph	nysical and Chemical Properties	
Section 9, Physical and chemical prope	erties	
Physical State		
	Capsules	
Solubility	Capsules Freely soluble in dimethylformamide, insoluble in hot and cold water.	
Solubility Odor	Freely soluble in dimethylformamide, insoluble in	
-	Freely soluble in dimethylformamide, insoluble in hot and cold water.	



"Hetero Corporate", 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018. A.P., INDIA. Tel : 91-40-23704923/24/25, Fax : 91-40-23704926, 23714250 e-mail : contact@heterodrugs.com URL : http://www.heterodrugs.com

Evaporation rate: Not Available	Vapour density: Not Available				
Reactivity in water: Not Available	Vapour pressure: Not Available				
Percentage Volatile by volume: Not Available	Specific gravity: Not Available				
Section 10: Stability and Reactivity					
Condition to avoid: Avoid exposure to extreme heat light and moisture.	³ Stable: Product is stable				
Incompatibilities: Reacting with oxidizing substance					
Section 11: Toxic	ological Information				
General Information	Handling of formulated product is not expected to cause any toxicological affects. The data pertains to the ingredient in formulations, rather than this specie Formulation.				
Target Organ	Eye contact, Skin contact and inhalation is not great risk as this product is capsule.				
Other	Oral lansoprazole doses up to 5000 mg/kg in rats [approximately 1300 times the 30 mg human dose based on body surface area (BSA)] and in mice (about 675.7 times the 30 mg human dose based or BSA) did not produce deaths or any clinical signs.				
Section 12: Ecolo	ogical Information				
Do not allow product to enter drinking water supplies, waste water or soil.					
Section 13: Dispo	sal Considerations				
Dispose the waste in accordance with all applicable F	ederal, State and local laws.				
Section 14: Tran	sport Information				
The product is not hazardous when shipping via air (I	ATA), ground (DOT), or sea (IMDG).				
Section 15: Regulatory Information					
Generic Medicine. Approved by USFDA					
Section 16: Other Information, includ	ing date of preparation or last revision				
Text of CLP/GHS Classification abbreviations mention	oned in Section 3				
None Issue Date: 20-05-2020 Version: 00					
Revision note: New					

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Hetero Labs Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Hetero Labs Limited reserves the right to revise this SDS.